Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Xiuning Le, Antonio Passaro, Yuanyuan Zhao, Yan Huang, Janessa Laskin, Delvys Rodriguez-Abreu, Antonio Calles, Lyudmila Bazhenova, Giuseppe Lo Russo, Natasha B Leighl, Federico Cappuzzo, Nicolas Girard, Sanjay Popat, Wenfeng Fang, Yongzhong Luo, Wenting Li, Zhiyong He, Hui Zhao, Mingjun Li, Qibin Song, Hongyun Zhao, Haidar El Darsa, Isabelle Monnet, Manuel Cobo Dols, Rosario García Campelo, Robert Jotte, David Berz, Alexander Spira, Maurice Pérol, Misako Nagasaka, Howard West, Lori Styles, Jianling Li, Fong Clow, Jonathan Goldman, Li Zhang

Open source

DOI: 10.1016/s1470-2045(26)00282-2
Published: 2026-09
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00282-2,
  title = {Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial},
  author = {Xiuning Le and Antonio Passaro and Yuanyuan Zhao and Yan Huang and Janessa Laskin and Delvys Rodriguez-Abreu and Antonio Calles and Lyudmila Bazhenova and Giuseppe Lo Russo and Natasha B Leighl and Federico Cappuzzo and Nicolas Girard and Sanjay Popat and Wenfeng Fang and Yongzhong Luo and Wenting Li and Zhiyong He and Hui Zhao and Mingjun Li and Qibin Song and Hongyun Zhao and Haidar El Darsa and Isabelle Monnet and Manuel Cobo Dols and Rosario García Campelo and Robert Jotte and David Berz and Alexander Spira and Maurice Pérol and Misako Nagasaka and Howard West and Lori Styles and Jianling Li and Fong Clow and Jonathan Goldman and Li Zhang},
  year = {2026},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(26)00282-2},
  url = {https://doi.org/10.1016/s1470-2045(26)00282-2}
}

RIS

TY  - JOUR
TI  - Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
AU  - Xiuning Le
AU  - Antonio Passaro
AU  - Yuanyuan Zhao
AU  - Yan Huang
AU  - Janessa Laskin
AU  - Delvys Rodriguez-Abreu
AU  - Antonio Calles
AU  - Lyudmila Bazhenova
AU  - Giuseppe Lo Russo
AU  - Natasha B Leighl
AU  - Federico Cappuzzo
AU  - Nicolas Girard
AU  - Sanjay Popat
AU  - Wenfeng Fang
AU  - Yongzhong Luo
AU  - Wenting Li
AU  - Zhiyong He
AU  - Hui Zhao
AU  - Mingjun Li
AU  - Qibin Song
AU  - Hongyun Zhao
AU  - Haidar El Darsa
AU  - Isabelle Monnet
AU  - Manuel Cobo Dols
AU  - Rosario García Campelo
AU  - Robert Jotte
AU  - David Berz
AU  - Alexander Spira
AU  - Maurice Pérol
AU  - Misako Nagasaka
AU  - Howard West
AU  - Lori Styles
AU  - Jianling Li
AU  - Fong Clow
AU  - Jonathan Goldman
AU  - Li Zhang
PY  - 2026
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(26)00282-2
UR  - https://doi.org/10.1016/s1470-2045(26)00282-2
ER  -

APA

Le, X., Passaro, A., Zhao, Y., Huang, Y., Laskin, J., Rodriguez-Abreu, D., Calles, A., Bazhenova, L., Russo, G. L., Leighl, N. B., Cappuzzo, F., Girard, N., Popat, S., Fang, W., Luo, Y., Li, W., He, Z., Zhao, H., Li, M., Song, Q., Zhao, H., Darsa, H. E., Monnet, I., Dols, M. C., Campelo, R. G., Jotte, R., Berz, D., Spira, A., Pérol, M., Nagasaka, M., West, H., Styles, L., Li, J., Clow, F., Goldman, J., & Zhang, L. (2026). Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00282-2

Source records

crossref · retrieved 2026-09-25T14:17:45.399Z